Business Wire

Danish Robotics Company Kobots Open to Investors

27.9.2021 16:09:00 EEST | Business Wire | Press release

Share

The people behind Kobots know that construction workers benefit from healthier, longer and more productive careers when robots are used to automate part of the workflow. Using the British crowdsourcing platform, Seedrs – which has no minimum investment requirement – Kobots is inviting everyone to invest in its robots to help the future of construction.

Sales of Kobots’ drywall cutting robot “Amigo” took off in 2020, and Kobots is raising 10 million Danish kroner (1.4 million Euro) to fund its international expansion. Amigo was developed by Danish carpenter Peter Hartvigsen to automatically cut drywall using measurements entered in a phone app.

Right now, Amigo is cutting 40,000 square metres of drywall used to construct the Danish highrise, Lighthouse.

“Amigo is perfect for Lighthouse because we have to cut so much drywall,” said Morten Kjaer, enterprise manager for Hustømrerne A/S, which works on LightHouse. “It allows us to keep a fast pace on the construction site.”

Dust reduction means big benefits to the work environment

Construction dust related lung disease takes the lives of 250 Danish workers annually.

Jonas Nymark hangs drywall at the Lighthouse site and he says the robot makes a huge difference in air quality.

“It's scary: we used to have at least three times as much dust in the air before we started using Amigo,” Nymark said. “I don’t want to go back to working in all that dust.”

Nobody is too busy to automize

Since its introduction in 2020, Kobot’s Amigo has cut enough drywall to cover 24 football fields, and it has preserved 34 tonnes of materials by saving and automatically remembering to use smaller pieces.

“Any company that’s gotten a demo of Amigo has either purchased or leased the robot,” said Peter Hartvigsen. “Kobots is positioned right there on the hockey stick growth chart where things are really going to take off.”

Collaboration with Velux and James Hardie Group

Among Kobots’ owners are some of the Danish robotics industry’s heavy hitters, like Niels Jul Jacobsen, the man behind Mobile Industrial Robots and Capra Robotics.

Construction material producers Velux and James Hardie Group are also working with Kobots.

This Seedrs crowdfunding round kicks off on Oct. 11, 2021, and you can reach it here or you can register for a private investment that opens on Sept. 29, here.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Press
Kobots’ PR Consultant
Malene Grouleff
+45-28915809
malene@grouleff.it

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

CorFlow Therapeutics Announces Successful Completion of Phase 1 and First Patients Enrolled in Phase 2 of the MOCA II Pivotal Trial, Approval to Start the REVITALISE RCT in Europe, and Strengthening of Clinical Leadership30.4.2026 14:00:00 EEST | Press release

CorFlow Therapeutics AG (CorFlow), a clinical-stage company focused on transforming the diagnosis and treatment for heart attack patients, today announced multiple milestones in advancing its clinical program and the strengthening of clinical leadership. Phase 1 of the company’s MOCA II FDA Pivotal Trial was successfully reached after safety and performance goals were met with STEMI heart attack patients who had the proprietary PCoFI diagnostic measurement of microvascular obstruction (MVO) made during a stenting procedure, when compared to the reference standard diagnosis by cardiac MRI in the subsequent days. Phase 1 included 19 patients enrolled across 5 US and 3 European sites. MOCA II follows the FIH MOCA I study and primarily aims to validate the threshold value of the proprietary PCoFI measurement for diagnosing MVO in the setting of primary angioplasty compared to cardiac MRI. This milestone achievement, which was confirmed by the study’s independent DSMB (Data and Safety Monit

Agendia to Present New Data Demonstrating the Expanded Clinical Utility of MammaPrint ® and BluePrint ® at the 2026 ESMO Breast Cancer Annual Congress30.4.2026 14:00:00 EEST | Press release

Agendia®, Inc., a leader in precision oncology for breast cancer, today announced it will present new data at the 2026 European Society for Medical Oncology (ESMO) Annual Congress on Breast Cancer, taking place May 6-8 in Berlin, Germany. The company will present two posters featuring data from the prospective FLEX Study and an independent post hoc analysis of the landmark MINDACT trial that underscore the prognostic value of MammaPrint® + BluePrint® in early-stage breast cancer (EBC). Poster #65P | Thursday, May 7, 13:15 – 14:15 p.m. CEST | Presenter: Elena Shagisultanova Prognostic Performance of MammaPrint in Patients with Small T1a, b, and c Node-Negative Early Breast Cancer A retrospective analysis from the FLEX Study involving 4,349 patients highlights the biological heterogeneity within small, node-negative (T1a, b, and c) tumors – a group that typically has favorable outcomes. MammaPrint (MP) identified a High Risk 2 (H2) subset, representing 10% of all patients and 5% of those

The Biggest Predictor of Business Growth Is Behavior30.4.2026 10:00:00 EEST | Press release

IDEO, the global design and innovation company, today announced the IDEO Innovation Quotient (IDEO IQ), a new report measuring how workplace behaviors drive business performance across 100 of the world’s largest companies. Those with the highest IDEO IQ scores earned nearly $20 billion in profit last year—50% higher than average and three times more than those ranked at the bottom. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429978890/en/ The IDEO Innovation Quotient (IDEO IQ) is a new report measuring how workplace behaviors drive business performance across 100 of the world’s largest companies. The IDEO IQ surveyed 266 leaders in product and innovation roles at 100 of the world’s largest companies across the Media & Technology, Healthcare, and Consumer Goods sectors. The report is the first of its kind to draw a direct line between how companies operate internally and their financial performance. Companies were surve

Suzano Sells 12.7 Million Tonnes of Pulp for the First Time in Its History30.4.2026 01:22:00 EEST | Press release

Suzano(B3: SUZB3 | NYSE: SUZ), the world’s largest pulp producer, announces its results for the first quarter of 2026 (1Q26), achieving a new all‑time record in pulp sales. Over the 12‑month period from April 2025 to March 2026, the company sold 12.7 million tonnes of pulp, the highest volume ever recorded in its history. During the same period, Suzano also sold 1.7 million tonnes of paper across the packaging, printing and writing, specialty, and tissue segments. This unprecedented sales level mainly reflects the increase in production capacity following the start‑up of the Ribas do Rio Pardo pulp mill in the state of Mato Grosso do Sul, as well as Suzano’s strong operational efficiency across its production lines and supply chains, serving customers in more than 100 countries worldwide. In the first quarter of 2026, Suzano sold a total of 3.2 million tonnes, comprising 2.8 million tonnes of pulp and 378 thousand tonnes of paper. Net revenue amounted to BRL 11.0 billion, while adjuste

The Estée Lauder Companies Announces Minority Investment in Luxury Clinical Skin Care Brand 111SKIN29.4.2026 23:30:00 EEST | Press release

The Estée Lauder Companies Inc. (NYSE:EL) today announced a minority investment in 111SKIN, a luxury clinical skin care brand founded by renowned plastic and reconstructive surgeon Dr. Yannis Alexandrides. Terms of the investment were not disclosed. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429495879/en/ 111SKIN's Reparative Collection Founded in 2012, 111SKIN was originally developed by Dr. Alexandrides to accelerate his patients’ healing time following procedures. At the heart of the brand is its innovative NAC Y2™, a pioneering complex designed to support skin repair and maintain a healthy, radiant and resilient complexion. Building on the foundation of this clinical expertise, 111SKIN has developed a portfolio of more than 30 products, anchored by its Black Diamond and Reparative collections and priced from $50 to $1,000. “Skin care is entering a new phase, shaped by the convergence of procedures, longevity and b

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye